First National Trust Co Sells 226 Shares of Stryker Corporation $SYK

First National Trust Co cut its stake in Stryker Corporation (NYSE:SYK) by 1.2% in the second quarter, Holdings Channel reports. The institutional investor owned 18,335 shares of the medical technology company’s stock after selling 226 shares during the period. First National Trust Co’s holdings in Stryker were worth $7,254,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in SYK. Vanguard Group Inc. lifted its stake in Stryker by 1.1% in the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after purchasing an additional 361,136 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after purchasing an additional 1,021,496 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Stryker by 13.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after acquiring an additional 261,058 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Stryker by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock worth $776,871,000 after acquiring an additional 83,954 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Stryker by 1.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,015,374 shares of the medical technology company’s stock worth $750,223,000 after acquiring an additional 30,329 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.5%

NYSE:SYK opened at $383.56 on Tuesday. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market cap of $146.64 billion, a P/E ratio of 50.80, a P/E/G ratio of 2.75 and a beta of 0.94. The firm has a 50-day simple moving average of $379.87 and a 200-day simple moving average of $380.29.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s payout ratio is presently 44.50%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SYK. BTIG Research lifted their target price on Stryker from $407.00 to $408.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. UBS Group set a $408.00 price objective on shares of Stryker in a report on Monday, October 13th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Rothschild & Co Redburn initiated coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective for the company. Finally, Evercore ISI decreased their price target on shares of Stryker from $418.00 to $410.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average target price of $432.24.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.